KATIE URAM: Open Payments
NPI 1396023099 · WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$827 in 49 payments from 16 companies in 2025. Trend: 2023 $648 · 2024 $581 · 2025 $827
Food & beverage: $827
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $175 |
| PFIZER INC. | 10 | $166 |
| Lundbeck LLC | 3 | $84 |
| GlaxoSmithKline, LLC. | 3 | $64 |
| ABBVIE INC. | 3 | $62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $57 |
| Merck Sharp & Dohme LLC | 2 | $38 |
| Lilly USA, LLC | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
Products named: REXULTI, NURTEC ODT, TRELEGY ELLIPTA, JARDIANCE, Ozempic, PREVNAR 20, VRAYLAR, ELIQUIS.
Industry payments across PA — which companies pay providers there.
